SavedAdd your journal

Journals / Türk Klinik Biyokimya Dergisi / 2019 / Cilt: 17 - Sayı: 3

Early Prediction Of Crohn’s Disease Activity In Clinically Remission Patients

Klinik Remisyonda olan Crohn Hastalarında Hastalık Aktivitesinin Erken Öngörüsü

Güneş AK
Ömer ÖZÜTEMİZ
Nalan Gülşen ÜNAL
Burcu BARUTÇUOĞLU
Günel HASANOVA
Pages
140–148
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this study is to predict the CD activity by fecal calprotectin and fecal lactoferrin in clinically remission Crohn's disease patients.Materials and Methods: Twelve asymptomatic CD patients (CDAI

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Crohn's disease (CD) is an immunity-based inflammatory disease of unknown etiology which affects any region of the gastrointestinal tract with transmural involvement.
📊
Key Findings & Data:In these patients; many clinical activity indicators and noninvasive markers have been used to assess disease activity, but none have been as accurate as histopathological and endoscopic examinations in detecting inflammatory activity.
💡
Conclusion & Impact:The aim of this study is to predict the CD activity by fecal calprotectin and fecal lactoferrin in clinically remission Crohn's disease patients.Materials and Methods: Twelve asymptomatic CD patients (CDAI
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Crohn's disease (CD) is an immunity-based inflammatory disease of unknown etiology which affects any region of the gastrointestinal tract with transmural involvement. In these patients; many clinical activity indicators and noninvasive markers have been used to assess disease activity, but none have been as accurate as histopathological and endoscopic examinations in detecting inflammatory activity. In CD, disease activity is clinically determined by Crohn's Disease Activity Index (CDAI) score. According to CDAI, less than 150 points is accepted as remission, and over 450 points is a serious fulminant disease. The aim of this study is to predict the CD activity by fecal calprotectin and fecal lactoferrin in clinically remission Crohn's disease patients.Materials and Methods: Twelve asymptomatic CD patients (CDAI

Özet

Amaç: Crohn’s hastalığı (CH) gastrointestinal sistemin herhangi bir bölgesinde transmural tutulumu olan, etyolojisi bilinmeyen, immunite kökenli inflamatuvar bir hastalıktır. Bu hastalarda hastalık aktivitesini saptamak için birçok klinik aktivite indikatörü ve invazif olmayan göstergeler kullanılmıştır ancak, hiçbirihistopatolojik ve endoskopik incelemeler kadar doğru olmamaktadır. CH’nda, hastalık aktivitesi klinik olarak Crohn’s Hastalığı Aktivite indeksi (CDAI) ile saptanmaktadır. CDAI’e göre 150 puanın altı remisyonve 450 puan üzeri ciddi fulminan hastalık olarak kabul edilmektedir. Bu çalışmanın amacı klinik remisyondaki CH’da hastalık aktivitesini fekal kalprotektin ve fekal laktoferrin ile öngörmektir.Gereç ve Yöntem: Gastroenteroloji polikliniğe başvurulan on iki asemptomatik CH’sı (CDAI

🔖

Cite This Article

AK, G., ÖZÜTEMİZ, Ö., ÜNAL, N. G., BARUTÇUOĞLU, B., HASANOVA, G. (2022). Early Prediction Of Crohn’s Disease Activity In Clinically Remission Patients. Türk Klinik Biyokimya Dergisi, Cilt: 17 - Sayı: 3, 140–148. https://ajindex.com/articles/634366

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007
  2. PMID:17653185 DOI: 10.1038/nature06005 2. Sostegni R, Daperno M, Scaglione N et al. Review article: Crohn’s disease: monitoring disease activity Aliment Pharmacol Th er 2003
  3. Schoepfer AM, Vavricka S, Zahnd-Straumann N, Straumann A, Beglinger C. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis 2012
  4. [PMID: 22398068 DOI: 10.1016/j.crohns.2011. 09.008 4. Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, et al
  5. European Crohn’s and Colitis Organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013
  6. [PMID: 24184171 DOI: 10.1016/j.crohns.2013.09.016 5. Bjerrum JT, Nielsen OH, Hao F, Tang H, Nicholson JK, Wang Y, Olsen J Metabonomics in Ulcerative Colitis: Diagnostics, Biomarker Identification, And Insight into the Pathophysiology. J Proteome Res 2010
  7. 954–962. 6. Boschetti G, Laidet M, Moussata D, et al (2015) Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn’s Disease. Am J Gastroenterol 110:865–872 7. Krzesiek E. Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children. Adv Clin Exp Med 2015
  8. 815–822. 8. Yamamoto T, Shimoyama T. Can Fecal Biomarkers Detect Ileal Inflammation in Inflammatory Bowel Disease? Am J Gastroenterol 2015
  9. 1370–1370. 9. Dai C, Jiang M, Sun M-J (2017) Fecal Calprotectin in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. Dig Dis Sci. 2017
  10. 62(12):3625–26. doi: 10.1007/s10620-017- 4799-0 10. Klimczak K, Lykowska-Szuber L, Eder P, KrelaKazmierczak I, Stawczyk-Eder K, Szymczak A, Michalak M, et al. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn’s disease activity. Eur J Intern Med 2015
  11. 623–627. 11. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2015
  12. 802–819. 12. Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, et al. Development and validation of a new, simplified endoscopic activ